Avatrombopag Oral Tablet

DRUG2 trials

Sponsors

Sobi, Inc.

Conditions

Immune Thrombocytopenia

Phase 3

Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP

CompletedNCT05369208

Sobi, Inc.Immune Thrombocytopenia

Start: 2022-06-15End: 2025-10-29Updated: 2026-06-03

Phase 4

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

CompletedNCT04638829

Sobi, Inc.Immune Thrombocytopenia

Start: 2021-03-15End: 2024-01-03Updated: 2025-01-16

Related Papers

Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA

Blood Advances2025-03-182 citations

Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim

Blood2024-11-05

Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-Hoc Analyses from a Prospective Phase 4 Study

Blood2024-11-05

Interim Analysis of Platelet Response in a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA)

Blood2023-11-021 citations

Interim Analysis of Treatment Satisfaction from a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag or Romiplostim to Avatrombopag

Blood2023-11-02

PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM

HemaSphere2023-08-011 citations